Compare Repligen Corporation Common Stock (RGEN) vs Vital Farms Inc (VITL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs Vital Farms Inc — how do they compare? Repligen Corporation Common Stock trades at $178.15 (market cap $11.31B), while Vital Farms Inc trades at $8.92 (market cap $400.98M). The key difference: Repligen Corporation Common Stock is far larger — about 28.2× Vital Farms Inc's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, Vital Farms Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Vital Farms Inc for 15 Days on average.
| RGEN | VITL | |
|---|---|---|
Market Cap | $11.31B | $400.98M |
Volume | 1,216,919 | 1,181,598 |
Sector | Health | Consumer Staples |
52-Week High | $194.57 | $40.85 |
52-Week Low | $102.87 | $8.28 |
Typical Hold Time | 0 Days | 15 Days |
Enterprise Value | $11.20B | $487.99M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Vital Farms (VITL) trades at $9.34, down 1.37% amid bearish technical signals and challenging fundamentals. The stock faces pressure from declining earnings, with Q1 2026 missing expectations and Q3 2026 expected at -$0.13 EPS. Despite a 56% analyst buy rating and $13.11 consensus target, recent news highlights strategic review discussions and pricing pressures in the egg market. Revenue remains flat at $766M for 2026 with net margins collapsing to near-zero, while cash flow trends show significant operational challenges.
The outlook remains cautious with near-term headwinds from industry oversupply and margin compression. Investment opportunity exists if strategic options materialize, but risks include sustained profitability challenges and competitive pressures. Current valuation metrics suggest potential upside if execution improves, but investors should monitor Q3 earnings and strategic developments closely.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About Vital Farms Inc
Vital Farms is a leading provider of ethically produced, pasture-raised eggs and butter in the United States. Operating as a Public Benefit Corporation, it manages a network of over 650 family farms to deliver high-welfare food products. It leverages a scalable 'asset-light' partnership model that prioritizes transparency and animal welfare to meet the growing consumer demand for clean-label and sustainable food sources.
Read more on VITL →
